[1] Ott JJ,Stevens GA,Groeger J,et al. Global epidemiology of hepatitis B virus infection:new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine,2012,30:2212-2219.
[2] Lozano R,Naghavi M,Foreman K,et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:a systematic analysis for the Global Burden of Disease Study 2010. Lancet,2012,380:2095-2128.
[3] Lu FM,Zhuang H. Management of hepatitis B in China. Chin Med J (Engl),2009,122:3-4.
[4] Wang FS,Fan JG,Zhang Z,et al. The global burden of liver disease:The major impact of China. Hepatology,2014,60:2099-2108.
[5] 李志刚.103例乙型肝炎免疫耐受期患者抗病毒的疗效分析.中国实用医药,2011,24:17-18.
[6] 中华医学肝病学分会,中华医学会感染分会中国慢性乙型肝炎防治指南(2015版).中国肝脏病杂志,2015,03:1-18.
[7] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J Hepatol,2012,57:167-185.
[8] 邢汉前,辛绍杰,张欣,等.慢性乙型肝炎病毒感染免疫耐受期患者的临床病理特征. 世界华人消化杂志,2006,14:1425-1429.
[9] Parkin DM,Pisani P,munoz N,et al. The global health burnden of infection addociated cancer Surv. 1999,33:5-33.
[10] 陈园生,梁晓峰,胡俊峰.乙型肝炎病毒感染血清学标志与慢性感染自然史研究进展.中国疫苗和免疫,2009,03:279-283.
[11] Liaw YE. Natural history of chronic hepatitis B virus infection and long-term outcome undertreatment. Liver Int,2009,29:100-107.
[12] Wursthorn K,Manns MP,Wedemeyer H. Natural history: the importance of viral load, liver damage and HCC.Best Pract Res Clin Gastroenterol,2008,22:1063-1079.
[13] Hann HW,Han SH,Block TM,et al. Symptomatology and health attitudes of chronic hepatitis B patients in the USA. J Viral Hepat,2008,15:42-51.
[14] Prendergast AJ,Klenerman P,Goulder PJ.The impact of differential antiviral immunity in children and adults. Nat Rev Immunol,2012,12:636-648.
[15] 谢晶日,李婷婷,李明,等. 慢性乙型病毒性肝炎免疫耐受的研究进展. 中华中医药学刊,2014,01:12-14.
[16] Yim HJ,Lok AS. Natural history of chronic hepatitis B virus infection:what we knew in 1981 and what we know in 2005.Hepatology,2006,43:S173-S181.
[17] Chen L,Zhang Z,Chen W,et al. B7-Hl up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J Immunol,2007,178:6634-6641.
[18] 廖雪姣,何清,杨大国,等. 637例慢性HBV感染者自然史各期肝组织纤维化演变规律研究. 中国肝脏病杂志(电子版),2014,02:1-5.
[19] Chu CM,Liaw YF. Chronic hepatitis B virus infection acquired in childhood:special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat,2007,14:147-152.
[20] Andreani T,Serfaty L,Mohand D,et al. Chronic hepatitis B virus carriers in the immunotolerant phase of infection:histological findings and outcome. Clin Gastroenterol Hepatol ,2007,5:636-641.
[21] Kao JH,Chen DS. Critical analysis of the immune tolerance phase of chronic HBV infection:natural history and diagnosis. Curr Hepat Rep,2008,7:5-11.
[22] Guidelines for the Prevention,Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva:World Health Organization,2015.
[23] 曾祥华,石代蓉,王宇明. FibroScan用于慢性肝病临床诊治新进展. 中国实用内科杂志,2014,12:1185-1188.
[24] 苏冬娜,吴诗品,汤小俐. Fibroscan对乙型肝炎病毒携带者纤维化的诊断. 暨南大学学报(自然科学与医学版),2015,05:435-438.
[25] 戴雯,代倩,李晶晶,等. FibroTouch无创诊断慢性HBV感染者肝纤维化程度的临床价值. 安徽医科大学学报,2016,09:1338-1342.
[26] 欧晓娟,王晓明,吴晓宁,等. Fibro Touch与Fibro Scan在慢性乙型肝炎患者肝纤维化评估中的比较. 中华肝脏病杂志, 2015, 23:3-6.
[27] 黄珊,何清,唐奇远,等. 112例慢性HBV感染免疫耐受期患者肝组织病理学特点. 中国肝脏病杂志(电子版),2011,04:16-21.
[28] 陈丽,周兴蓓,温丹凤,等. 肝功能正常的慢性HBV感染者的临床特征及肝脏病理学分析. 临床肝胆病杂志,2015,09:1430-1433.
[29] Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016,10:7-8.
[30] Kim HC,Nam CM,Jee SH,et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases:prospective cohort study. BMJ,2004,328:980-983.
[31] American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology,2016,63:261-283.
[32] Tsen TC,Kao JH.Treating immune-tolerant hepatitis B. J Viral Hepat,2015,22:77-84. |
